Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
PBYI Puma Biotechnology
4.520+0.060+1.35%
Close
02/06 16:00 ET
4.5200.0000.00%
Post Mkt Price 02/06 16:12 ET
High
4.710
Open
4.450
Turnover
1.07M
Low
4.310
Pre Close
4.460
Volume
234.41K
Post-Market
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Puma Biotechnology Says NCCN Clinical Practice Adds Breast Cancer Drug Nerlynx to Guidelines
04:10 PM EST, 02/01/2023 (MT Newswires) -- Puma Biotechnology (PBYI) said Wednesday neratinib, or Nerlynx, has been included in the National Comprehensive Cancer Network Clinical Practice guidelines f
H.C. Wainwright Reaffirms Their Buy Rating on Puma Biotechnology (PBYI)
Puma's Nerlynx Included in NCCN Guidelines for HER2-positive Breast Cancer
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200-Day Moving Average of $3.39
Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) shares passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.39 and traded as high as $
Spero Therapeutics (NASDAQ:SPRO) and Puma Biotechnology (NASDAQ:PBYI) Head-To-Head Comparison
Spero Therapeutics (NASDAQ:SPRO – Get Rating) and Puma Biotechnology (NASDAQ:PBYI – Get Rating) are both small-cap medical companies, but which is the better stock? We will compare the two companies
Puma Biotechnology (NASDAQ:PBYI) Shares Cross Above 200 Day Moving Average of $3.27
Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $3.27 and traded as high as $4.80. P
Puma Biotechnology to Present at B. Riley Securities' 3rd Annual Oncology Conference
Puma Biotechnology, Inc. (NASDAQ:PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:00
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on January 10, 2023, the Compensation Committee of Puma's Board of Directors approved
Puma Biotechnology Releases Updated Corporate Presentation
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, provided an update to the corporate presentation that its Chief Executive Officer and President, Ala
Insider Selling: Puma Biotechnology, Inc. (NASDAQ:PBYI) CFO Sells $43,885.82 in Stock
Puma Biotechnology, Inc. (NASDAQ:PBYI – Get Rating) CFO Maximo F. Nougues sold 10,499 shares of Puma Biotechnology stock in a transaction on Tuesday, January 3rd. The shares were sold at an average p
Company Overview
More
Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.
CEO： Mr. Alan H. Auerbach
Market： NASDAQ
Listing Date： 03/21/2012
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet